Latest Breaking News On - Founded october - Page 1 : comparemela.com

Life after Davis Langdon

and a spate of start-ups This piece about the spin-off firms in the wake of the Aecom takeover of DL is republished as it appeared in 2013 with the subheading Building profiles the many new start-ups launched by former Davis Langdon partners When Building broke the news this month that six former partners of Davis Langdon were setting up a consultant of their own - to be called Alinea - regular readers may have had a feeling of deja vu. Hadn’t we been here before? Yes, indeed, at least 15 times in two-and-a-half years. The reasons for such a proliferation of Davis Langdon (DL) staff exiting to go it alone are many and varied – and well-rehearsed. See our January feature on the ‘Culture Shock’ at DL following its 2010 takeover by Aecom for a detailed analysis.

New yorkUnited statesCity of londonCity ofUnited kingdomAd daw ahUnited arab emiratesHong kongBorough of bedfordDaniel fryerMark baxterRichard hopperAlex walkerAbu dhabiPaul allenTim beresford

Kibow Biotech Announces FDA Approval of IND to Initiate Phase II Clinical Trial of US-APR2020 to Treat Chronic Kidney Disease Stage IV

Published: Apr 13, 2021 NEWTOWN SQUARE, Pa., April 13, 2021 /PRNewswire/ Kibow Biotech, Inc. a clinical-stage biotechnology company pioneering the discovery and development of probiotics and prebiotics (synbiotics) for the treatment of kidney diseases beyond gut health, today announced that the U.S. Food and Drug Administration (FDA) had approved the Company s Investigational New Drug Application (IND) for US-APR2020 to treat patients with Chronic Kidney Disease (CKD) stage IV. The primary efficacy endpoint for the multisite trial is to arrest the decline of estimated Glomerular Filtration Rate (eGFR) by 40% from baseline as per the American Society of Nephrology (ASN), National Kidney Foundation (NKF), and US FDA (https://pubmed.ncbi.nlm.nih.gov/25441437/).

United statesNewtown squareNatarajan ranganathanMukesh kumarEmmanuel anteyiBrij strategic consultationsCompany investigational new drug applicationDrug administrationKibow biotech incNational kidney foundationKibow pharmaceuticalsAmerican society of nephrologyKibow biotechInvestigational new drug applicationChronic kidney diseaseGlomerular filtration rate

Kibow Biotech Announces FDA Approval of IND to Initiate Phase II Clinical Trial of US-APR2020 to Treat Chronic Kidney Disease Stage IV

Kibow Biotech Announces FDA Approval of IND to Initiate Phase II Clinical Trial of US-APR2020 to Treat Chronic Kidney Disease Stage IV
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesNewtown squareNatarajan ranganathanMukesh kumarEmmanuel anteyiBrij strategic consultationsCompany investigational new drug applicationDrug administrationKibow biotech incNational kidney foundationKibow pharmaceuticalsAmerican society of nephrologyKibow biotechInvestigational new drug applicationChronic kidney diseaseGlomerular filtration rate

Kibow Biotech Announces FDA Approval of IND to Initiate Phase II Clinical Trial of US-APR2020 to Treat Chronic Kidney Disease Stage IV

Kibow Biotech Supports World Kidney Day 2021

Kibow Biotech Supports World Kidney Day 2021 News provided by Share this article Share this article NEWTOWN SQUARE, Pa., March 11, 2021 /PRNewswire/ Kibow Biotech is pleased to support World Kidney Day s global campaign to raise awareness of the importance of our kidneys to overall health and to reduce the frequency and impact of kidney disease and associated health problems worldwide. Kibow will mark World Kidney Day, March 11, 2021, with a significant social media campaign to increase awareness of the importance of maintaining kidney function and remembering the kidney transplant shortage that affects patients worldwide. Throughout 23-years of continuous R&D, Kibow Biotech s dedicated staff have been privileged to provide support to people worldwide in their struggle with kidney function problems with RENADYL™ (See: www.RENADYL.com).

Newtown squareUnited statesWhite houseDistrict of columbiaMahesh ranganathanHuman services onKibow biotech incAmerican kidney healthKibow pharmaceuticalsDepartment of healthUremic toxin reduction technologyBusiness developmentKibow biotechWorld kidney dayInvestigational new drugBiologics evaluation